| Q38953228 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial |
| Q47973074 | 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial |
| Q57057499 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines |
| Q43784378 | 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. |
| Q92614348 | 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial |
| Q92614334 | 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial |
| Q28547962 | A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results |
| Q90589232 | A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell |
| Q39559549 | A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. |
| Q38029563 | A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). |
| Q37411548 | A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment |
| Q33823991 | A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study. |
| Q37107395 | A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer |
| Q37418498 | A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach |
| Q88779907 | A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery |
| Q40556214 | A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group st |
| Q45812913 | A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer |
| Q90101142 | A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study |
| Q34164735 | A review on various targeted anticancer therapies |
| Q37915362 | A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer |
| Q35145667 | A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis |
| Q37927091 | AE37: a novel T-cell-eliciting vaccine for breast cancer |
| Q39232309 | Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues. |
| Q37837267 | Added value of molecular targeted agents in oncology |
| Q57107802 | Adjuvant Anthracyclines in Breast Cancer: What Is Their Role? |
| Q27025860 | Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? |
| Q48262294 | Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. |
| Q37440847 | Adjuvant chemotherapy for early breast cancer in the elderly |
| Q34251780 | Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study |
| Q54244722 | Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. |
| Q26741523 | Adjuvant systemic therapy in older women with breast cancer |
| Q37376169 | Adjuvant targeted therapy in early breast cancer. |
| Q35051256 | Adjuvant therapy for women over age 65 with breast cancer |
| Q46431617 | Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial |
| Q35710898 | Adjuvant trastuzumab in HER2-positive breast cancer |
| Q54563619 | Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. |
| Q91738536 | Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis |
| Q36102808 | Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? |
| Q37601692 | Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. |
| Q34031225 | Advances in adjuvant systemic therapy for non-small-cell lung cancer |
| Q37823895 | Advances in cancer therapeutics and patient access to new drugs. |
| Q38681576 | Advances in systemic therapy for metastatic breast cancer: future perspectives. |
| Q37608406 | Advances in the adjuvant and neoadjuvant treatment of breast cancer |
| Q54407632 | An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. |
| Q34776985 | An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer |
| Q37158137 | Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer |
| Q37815614 | Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer |
| Q39686196 | Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells |
| Q36879470 | Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers |
| Q27026961 | Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma |
| Q33555569 | Are current drug development programmes realising the full potential of new agents? The scenario |
| Q54967616 | Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens. |
| Q36107134 | Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program |
| Q33751191 | Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. |
| Q39475977 | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers |
| Q47700657 | Assessment of HER-2 status in invasive breast cancer in Brazil. |
| Q39117949 | Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity |
| Q37057992 | Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers |
| Q36900970 | Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study |
| Q42176053 | Awareness and current knowledge of breast cancer. |
| Q30497664 | BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations |
| Q39973664 | BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation |
| Q40848631 | Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis. |
| Q36285897 | Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan |
| Q38015746 | Biological drugs: classic adverse effects and new clinical evidences |
| Q89673097 | Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients |
| Q92446296 | Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era |
| Q38696790 | Biomarker assessment and molecular testing for prognostication in breast cancer |
| Q38184380 | Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? |
| Q48737984 | Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer |
| Q35370118 | Breast cancer - one term, many entities? |
| Q42446359 | Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland |
| Q80442448 | Breast cancer clinical and translational research: analogies and implications for prostate cancer |
| Q37088027 | Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative |
| Q40650720 | Breast cancer survival in African-American women by hormone receptor subtypes. |
| Q37343294 | Breast cancer. Part 2: present and future treatment modalities |
| Q84065071 | Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective |
| Q38875316 | CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. |
| Q28282860 | CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer |
| Q42479947 | CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients |
| Q46172308 | CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary |
| Q54449440 | CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). |
| Q50531986 | Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. |
| Q54586053 | Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents? |
| Q85645292 | Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction? |
| Q81417332 | Cancer vaccines: on the threshold of success |
| Q38184648 | Cancer-testis genes as candidates for immunotherapy in breast cancer. |
| Q36485216 | Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. |
| Q40687353 | Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice |
| Q33724456 | Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial |
| Q84781418 | Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer |
| Q37716211 | Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer. |
| Q26851957 | Cardiac toxicity in cancer survivors |
| Q45182831 | Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium |
| Q37471532 | Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? |
| Q42373758 | Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. |
| Q37025960 | Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. |
| Q40218182 | Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). |
| Q39344380 | Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab |
| Q26766063 | Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management |
| Q33831903 | Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q36721511 | Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword |
| Q33949465 | Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors |
| Q38222800 | Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting. |
| Q82700421 | Challenging the dogma on trastuzumab: a matter of the heart |
| Q48306388 | Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. |
| Q37547962 | Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer |
| Q84510279 | Chemotherapy: Neoadjuvant trial design: time for a brave new world? |
| Q83140055 | Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series |
| Q37218987 | Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients? |
| Q41455102 | Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results |
| Q60949496 | Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data |
| Q37181068 | Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers |
| Q35625995 | Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. |
| Q53131225 | Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. |
| Q38153774 | Clinical practice-changing trials: the HERA study paradigm. |
| Q37602286 | Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept |
| Q36643018 | Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer |
| Q36591915 | Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer |
| Q37299843 | Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer |
| Q28830095 | Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma |
| Q26769610 | Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer |
| Q33799233 | Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer |
| Q50449083 | Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. |
| Q35854369 | Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer. |
| Q92837814 | Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China |
| Q35192288 | Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis |
| Q54550505 | Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. |
| Q89656068 | Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India |
| Q46569077 | Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium |
| Q64086900 | Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage -positive breast cancer |
| Q35070383 | Cost-effectiveness analysis of breast cancer control interventions in Peru |
| Q35620673 | Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. |
| Q39016850 | Current Trends in Multidrug Optimization |
| Q35164938 | Current neoadjuvant treatment options for HER2-positive breast cancer |
| Q34355748 | Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance |
| Q37063510 | Current status of antivascular therapy and targeted treatment in the clinic |
| Q26752024 | Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients |
| Q34621219 | Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients |
| Q38087507 | Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. |
| Q88511739 | DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine |
| Q39005417 | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
| Q57599812 | Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules |
| Q36664263 | Development of new therapy for canine mammary cancer with recombinant measles virus |
| Q35889621 | Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation |
| Q33843810 | Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab |
| Q36502589 | Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. |
| Q37240710 | Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial |
| Q38629753 | Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China |
| Q37314999 | Divide and conquer: progress in the molecular stratification of cancer |
| Q46521614 | Divisional role of quantitative HER2 testing in breast cancer |
| Q37822734 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? |
| Q34974213 | Do economic evaluations of targeted therapy provide support for decision makers? |
| Q84460916 | Do economic evaluations of targeted therapy provide support for decision makers? |
| Q53175518 | Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer. |
| Q38875428 | Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells |
| Q36281513 | Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials |
| Q36875361 | Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction |
| Q36875372 | Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea |
| Q34468964 | Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial |
| Q54117733 | Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. |
| Q35603664 | Droplet digital PCR measurement of HER2 in patients with gastric cancer |
| Q37204974 | Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer |
| Q36999509 | Drug resistance and the role of combination chemotherapy in improving patient outcomes |
| Q37940203 | Dual HER2-targeted approaches in HER2-positive breast cancer |
| Q36585794 | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function |
| Q83403908 | Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer |
| Q46714567 | Duration of adjuvant trastuzumab: shorter beats longer |
| Q38368230 | EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology |
| Q35765844 | ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide |
| Q33829405 | ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression |
| Q57142283 | Early breast cancer |
| Q36729600 | Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab |
| Q92354894 | Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer |
| Q36530791 | Effect of HER2 status on distant recurrence in early stage breast cancer |
| Q34427448 | Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer |
| Q37136423 | Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study |
| Q37287564 | Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective |
| Q37682591 | Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors |
| Q55314739 | Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. |
| Q39359785 | Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells. |
| Q55411853 | Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. |
| Q47768978 | Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study |
| Q35584206 | Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study |
| Q35067584 | Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases |
| Q37593371 | Emerging targeted combinations in the management of breast cancer |
| Q26824799 | Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer |
| Q42281218 | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers |
| Q89907217 | Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle |
| Q48829653 | Epidemiology of brain metastases |
| Q34793432 | Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy. |
| Q40103650 | Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type. |
| Q46624267 | European oncologists' preferences for the management of breast cancer: case presentations and expert commentary |
| Q28066481 | Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer |
| Q37562651 | Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases |
| Q48550447 | FISH in triple-negative breast cancer: a possible strategy for the future? |
| Q84903929 | Facilitating consensus by examining patterns of treatment effects |
| Q35948012 | Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab |
| Q37263863 | Facts and controversies in the use of trastuzumab in the adjuvant setting |
| Q45985434 | Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. |
| Q45917757 | First annual Canadian Cardiac Oncology Network conference. |
| Q81248961 | Follow-on biologics: data exclusivity and the balance between innovation and competition |
| Q33964848 | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. |
| Q33379276 | Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers |
| Q93074554 | From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand |
| Q34991701 | Frontiers of cancer care in Asia-Pacific region: cancer care in Australia |
| Q51739953 | Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. |
| Q81967929 | Funding a clinical trial: the perspective of a medicines funder |
| Q35625349 | Gastric cancer and the epoch of immunotherapy approaches |
| Q37273147 | Gated cardiac SPECT: can it be used for serial assessment of left ventricular function in oncology patients? |
| Q35990886 | Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial |
| Q43107261 | Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer |
| Q37169835 | Gene expression profiling: changing face of breast cancer classification and management |
| Q64111570 | Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer |
| Q37682675 | Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. |
| Q37687943 | Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry |
| Q54727540 | HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification. |
| Q37077883 | HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review |
| Q28237833 | HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer |
| Q36408890 | HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India |
| Q38704133 | HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer |
| Q35320325 | HER2 and breast cancer stem cells: more than meets the eye. |
| Q37705396 | HER2 as a target for breast cancer therapy. |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q37303196 | HER2 breast cancer therapies: a review |
| Q42431264 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing |
| Q36693285 | HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. |
| Q36849324 | HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population |
| Q43511214 | HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study |
| Q54340137 | HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). |
| Q27006811 | HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity |
| Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
| Q53657591 | HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. |
| Q34328064 | HER2 signaling pathway and trastuzumab cardiotoxicity |
| Q34062418 | HER2 status and breast cancer therapy: recent advances |
| Q46713075 | HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer |
| Q38151672 | HER2 therapies and gastric cancer: a step forward. |
| Q92577910 | HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study |
| Q39147155 | HER2-Orientated Therapy in Early and Metastatic Breast Cancer |
| Q37468290 | HER2-positive gastric cancer |
| Q37355586 | HER2-positive male breast cancer: an update. |
| Q35622862 | HER2: biology, detection, and clinical implications |
| Q37778843 | HER3 mRNA as a predictive biomarker in anticancer therapy |
| Q54609798 | HERA crosses over. |
| Q36611011 | Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. |
| Q37038467 | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study |
| Q83497497 | Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis |
| Q34256705 | Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells. |
| Q59340503 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis |
| Q37142882 | High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. |
| Q50990782 | High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. |
| Q39645914 | High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer |
| Q34048024 | High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer |
| Q37826199 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? |
| Q37170626 | How to interpret figures in reports of clinical trials |
| Q41350586 | Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics |
| Q36028694 | Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature |
| Q51823758 | Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. |
| Q33802832 | Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters |
| Q39661792 | Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study |
| Q36429835 | Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study. |
| Q35018233 | Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease |
| Q34336054 | Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. |
| Q41728685 | IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. |
| Q89839189 | Iatrogenic Decompensated Heart Failure |
| Q95322793 | Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma |
| Q35057976 | Immune effects of trastuzumab |
| Q64917530 | Impact of molecular testing in clinical practice in gynecologic cancers. |
| Q91272391 | Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results |
| Q45218109 | Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? |
| Q42036423 | Improving clinical trial efficiency by biomarker-guided patient selection |
| Q35949304 | Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer |
| Q34129444 | Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study |
| Q36746331 | Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies |
| Q26776198 | Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features |
| Q50866526 | Initiation of a formalized precision medicine program in gynecologic oncology. |
| Q39207741 | Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies |
| Q36062188 | Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient |
| Q31048851 | Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment |
| Q37811648 | Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? |
| Q36440625 | Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy |
| Q37947900 | Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? |
| Q43215432 | It's all in for the HER family in tumorigenesis |
| Q37338235 | Jumping higher: is it still possible? The ALTTO trial challenge |
| Q90836127 | Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study |
| Q34307423 | Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening |
| Q39676973 | Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells |
| Q39746124 | Lack of uniformity in cardiac assessment during trastuzumab therapy |
| Q37810946 | Lapatinib for breast cancer: a review of the current literature |
| Q39109847 | Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines |
| Q27851705 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial |
| Q37330143 | Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? |
| Q38982319 | Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool? |
| Q24321567 | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 |
| Q39500625 | Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Random |
| Q38654181 | Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype |
| Q44312876 | Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer |
| Q47602301 | Long-Term and Latent Side Effects of Specific Cancer Types |
| Q30371966 | Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. |
| Q58568604 | Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer |
| Q38693617 | MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. |
| Q34033952 | MET receptor sequence variants R970C and T992I lack transforming capacity |
| Q55395400 | Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. |
| Q37625436 | Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q36791451 | Management of breast cancer--Part II. |
| Q37123487 | Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring |
| Q38041467 | Management of small HER2 overexpressing tumours |
| Q37815282 | Management of small HER2-positive breast cancers |
| Q35155460 | Management options in triple-negative breast cancer |
| Q36410651 | Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer |
| Q55206328 | Media influence on Herceptin subsidization in Australia: application of the rule of rescue? |
| Q36510119 | Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma |
| Q30249335 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. |
| Q37785380 | Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy |
| Q36407511 | Metastasis: recent discoveries and novel treatment strategies |
| Q57838205 | Metastatic Spine Tumor Epidemiology: Comparison of Trends in Surgery Across Two Decades and Three Continents |
| Q39214783 | MiR-199b-5p targets HER2 in breast cancer cells |
| Q84830557 | Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab |
| Q37660907 | Molecular predictors of response to trastuzumab and lapatinib in breast cancer. |
| Q27025966 | Monoclonal antibodies for the treatment of cancer |
| Q36293907 | Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective |
| Q94475380 | Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer |
| Q43180234 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall |
| Q37638082 | Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. |
| Q38692311 | Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. |
| Q38926246 | New drug developments in psychosis: Challenges, opportunities and strategies |
| Q52666594 | New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. |
| Q34941536 | New network topology approaches reveal differential correlation patterns in breast cancer |
| Q37144315 | New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available |
| Q34421696 | Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer |
| Q90439922 | Novel Chemo-Photothermal Therapy in Breast Cancer Using Methotrexate-Loaded Folic Acid Conjugated Au@SiO2 Nanoparticles |
| Q47115287 | Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. |
| Q37523202 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. |
| Q38152899 | Novel cancer therapies: treatments driven by tumour biology |
| Q27011232 | Novel immunotherapeutic strategies of gastric cancer treatment |
| Q57578958 | Novel therapeutics in breast cancer—Looking to the future |
| Q39036113 | Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. |
| Q35780145 | Oligoclonal antibodies to target the ErbB family |
| Q36477760 | Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice |
| Q35583779 | Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider |
| Q34035460 | Optimizing the management of HER2-positive early breast cancer: the clinical reality |
| Q34064466 | Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma |
| Q37782094 | Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly |
| Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
| Q33411110 | Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation |
| Q34344198 | Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer |
| Q44806528 | Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab |
| Q36310182 | Personalized medicine in breast cancer: a systematic review |
| Q37241496 | Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies |
| Q37457684 | Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. |
| Q37163797 | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy |
| Q42749166 | Phorbol myristate acetate suppresses breast cancer cell growth via down-regulation of P-Rex1 expression |
| Q28742246 | Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth |
| Q37123529 | Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. |
| Q34189102 | Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity |
| Q33398378 | Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia |
| Q36950458 | Positron emission tomography imaging as a cancer biomarker |
| Q37921641 | Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer |
| Q54976923 | Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. |
| Q38047337 | Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. |
| Q38786102 | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge |
| Q42614878 | Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study |
| Q54326192 | Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. |
| Q37893531 | Pregnancy after breast cancer: if you wish, ma'am |
| Q53655466 | Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). |
| Q34967515 | Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer |
| Q37785387 | Prevention and management of major side effects of targeted agents in breast cancer |
| Q34996693 | Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines |
| Q54382690 | Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? |
| Q35583711 | Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status |
| Q37205563 | Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry |
| Q55261916 | Prognostic implications of HER2 heterogeneity in gastric cancer. |
| Q50848160 | Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. |
| Q39693600 | Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. |
| Q33915672 | Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer |
| Q64891425 | Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. |
| Q35029573 | Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers |
| Q27015506 | Quantification of HER family receptors in breast cancer |
| Q43254569 | Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. |
| Q92955572 | Quantitative microimmunohistochemistry for the grading of immunostains on tumour tissues |
| Q59361955 | Questions about adjuvant trastuzumab still remain |
| Q37821230 | RNA interference in the clinic: challenges and future directions |
| Q38542435 | RNA interference technology with emphasis on delivery vehicles-prospects and limitations |
| Q47565462 | RNA interference-based therapy and its delivery systems |
| Q37187716 | RNAi screen for rapid therapeutic target identification in leukemia patients |
| Q33306326 | RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia |
| Q41815741 | Radiation recall reaction induced by adjuvant trastuzumab (herceptin). |
| Q37694756 | Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells |
| Q33427353 | Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. |
| Q33973013 | Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr |
| Q35915758 | Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium |
| Q37208730 | Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. |
| Q44678963 | Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer |
| Q33862786 | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update |
| Q46558451 | Relative and disease-free survival for breast cancer in relation to subtype: a population-based study |
| Q48258787 | Reply to Kadri Altundag. |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q55182736 | Response: Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. |
| Q54379038 | Risk factors and survival outcome in cerebral metastatic breast cancer. |
| Q37800698 | Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis |
| Q54597919 | Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. |
| Q38103465 | Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. |
| Q35687465 | Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer |
| Q37371309 | Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer |
| Q37401837 | Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer |
| Q54593797 | Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. |
| Q98215219 | Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model |
| Q37746911 | Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology |
| Q37100575 | Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer |
| Q37206289 | Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial |
| Q35609706 | Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer |
| Q39775306 | Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls |
| Q39785686 | Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial |
| Q37701327 | Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate |
| Q34585338 | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer |
| Q33858930 | Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. |
| Q40748887 | Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer |
| Q37227392 | Single-antibody, targeted nanoparticle delivery of camptothecin |
| Q36032531 | Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer |
| Q37766678 | Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? |
| Q36682815 | Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer |
| Q57128759 | Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer |
| Q91713420 | Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target |
| Q38784568 | Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy |
| Q58876707 | Staging of cancer |
| Q84624513 | Statement: cancer treatments and ovarian reserve |
| Q35780315 | Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer |
| Q52691369 | Store operated calcium entry is altered by the inhibition of receptors tyrosine kinase. |
| Q36935421 | Studying copy number variations using a nanofluidic platform |
| Q38198973 | Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer |
| Q35948050 | Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model |
| Q47213396 | Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer |
| Q64906876 | Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. |
| Q35871467 | Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group |
| Q37814401 | Systematic review of pharmacoeconomic studies of pharmacogenomic tests |
| Q28260063 | Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline |
| Q39652258 | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions |
| Q37542931 | Systems pathology--taking molecular pathology into a new dimension |
| Q47559665 | Targeted Therapies Against Growth Factor Signaling in Breast Cancer |
| Q34096070 | Targeted Therapy for Early and Locally Advanced Breast Cancer |
| Q34042715 | Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? |
| Q34205672 | Targeted therapies for gastric cancer: current status |
| Q38019898 | Targeted therapy for gastric cancer--current status |
| Q37728765 | Targeted therapy in breast cancer: current status and future directions |
| Q35088311 | Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies |
| Q99408604 | Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications |
| Q55071512 | Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. |
| Q34272044 | Targeting HER2 in breast cancer: overview of long-term experience |
| Q84903918 | Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions |
| Q34880994 | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate |
| Q42326285 | Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? |
| Q38129286 | Targeting the ERBB family in cancer: couples therapy |
| Q35208654 | Targeting the HER/EGFR/ErbB family to prevent breast cancer. |
| Q37941807 | Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma |
| Q47736746 | The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries |
| Q35948882 | The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis |
| Q49544424 | The Dawning of Translational Breast Cancer: From Bench to Bedside |
| Q54298427 | The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. |
| Q37573820 | The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q40420807 | The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study |
| Q37626693 | The applications of pharmacogenetics to prescribing: what is currently practicable? |
| Q33595716 | The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure |
| Q37696505 | The cardiac safety of trastuzumab in the treatment of breast cancer |
| Q33378965 | The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer |
| Q37119179 | The emerging role of lapatinib in HER2-positive breast cancer |
| Q34363400 | The epidermal growth factor receptor family in breast cancer |
| Q30422987 | The evidence that evidence-based medicine omits |
| Q36294169 | The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study |
| Q33544010 | The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence |
| Q94570375 | The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors |
| Q36946585 | The history of myeloproliferative disorders: before and after Dameshek |
| Q94521566 | The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization |
| Q53179265 | The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. |
| Q44734963 | The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study |
| Q85074145 | The importance of the comparator in economic evaluations: working on the efficiency frontier |
| Q37087003 | The management of cancer in the elderly: targeted therapies in oncology |
| Q34376079 | The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors |
| Q33503737 | The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients |
| Q42380390 | The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform |
| Q35068343 | The role of HER-2 in Breast Cancer |
| Q38119251 | The role of the androgen receptor in triple-negative breast cancer |
| Q48150633 | The use of trastuzumab in New Zealand women with breast cancer |
| Q35608531 | Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. |
| Q37842506 | Therapeutic management of breast cancer in the elderly |
| Q35559932 | Therapeutic silencing of KRAS using systemically delivered siRNAs |
| Q37118500 | Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects |
| Q33522784 | Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias |
| Q51683826 | Translating the genomic architecture of breast cancer into clinical applications. |
| Q84244714 | Trastuzumab |
| Q42797006 | Trastuzumab (Herceptin ® ): Overcoming Resistance in HER2 -Overexpressing Breast Cancer Models |
| Q85110839 | Trastuzumab Cardio-Oncology: Lessons Learned |
| Q80029436 | Trastuzumab after adjuvant chemotherapy in older patients |
| Q37803118 | Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. |
| Q36361515 | Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models |
| Q37357924 | Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer |
| Q24200192 | Trastuzumab containing regimens for early breast cancer |
| Q54352756 | Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. |
| Q47795804 | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer |
| Q37633540 | Trastuzumab for gastric cancer |
| Q44007766 | Trastuzumab for gastric cancer treatment |
| Q37175884 | Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy |
| Q58130037 | Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction |
| Q38973381 | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| Q27851578 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial |
| Q81967926 | Trastuzumab in early-stage breast cancer: the question of treatment timing |
| Q43065085 | Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango! |
| Q33939795 | Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials |
| Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
| Q98289888 | Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling |
| Q33644305 | Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients |
| Q33727704 | Trastuzumab monotherapy for bone marrow metastasis of breast cancer: A case report |
| Q91788781 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients |
| Q37100311 | Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience |
| Q37477060 | Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities |
| Q48294650 | Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study |
| Q34538368 | Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study |
| Q39664583 | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer |
| Q33647686 | Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation |
| Q37766549 | Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer |
| Q31004660 | Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data |
| Q36933004 | Trastuzumab-induced hepatotoxicity: a case report |
| Q54705428 | Trastuzumab-related cardiac events in the treatment of early breast cancer. |
| Q37682882 | Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer |
| Q37846228 | Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer |
| Q36220464 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer |
| Q37213758 | Trastuzumab: a pharmacoeconomic review of its use in early breast cancer |
| Q81295719 | Trastuzumab: possible publication bias |
| Q39957050 | Trastuzumab: unusual responses and toxicities |
| Q33618132 | Treatment and survival in breast cancer in the Eastern Region of England |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
| Q36275971 | Treatment of HER2-positive metastatic breast cancer following initial progression |
| Q38155202 | Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts |
| Q37301426 | Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). |
| Q36864598 | Treatment of premenopausal women with early breast cancer: old challenges and new opportunities. |
| Q44806586 | Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy |
| Q91045690 | Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016) |
| Q37772792 | Treatment strategy for HER2-positive breast cancer |
| Q53158182 | Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. |
| Q33880165 | Trial watch: Immunostimulatory cytokines in cancer therapy |
| Q37356185 | Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women |
| Q36000688 | Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. |
| Q37548937 | Tumor dormancy and metastasis. |
| Q46305340 | Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. |
| Q82447162 | Unfavorable Drug Interactions in Targeted Breast Cancer Therapy |
| Q34043118 | Up-regulation of kin17 is essential for proliferation of breast cancer |
| Q39759252 | Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q57061765 | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
| Q47893099 | Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit |
| Q31122593 | Using clinical trial data to tailor adjuvant treatments for individual patients |
| Q33991804 | Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial |
| Q51755659 | Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. |
| Q39053758 | Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing? |
| Q37797337 | What's new in neoadjuvant therapy for breast cancer? |
| Q50747047 | Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? |
| Q60955770 | Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer |